Repaglinide Tablet
Product Images NDC 63629-4866

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Repaglinide (NDC 63629-4866). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl636294866)

Repaglinide Tablets, USP, 0.5 mg oral tablets, repackaged by Bryant Ranch Prepack and manufactured by Aurobindo Pharma Limited. The label shows NDC 63629-4866-1 and indicates a package containing 30 tablets. Storage instructions, child-resistant closure warning, and QR code for package insert are also visible.*

FDA Label Image

Figure 1: Repaglinide In Combination With Pioglitazone: Hba1c Values (Repaglinide Fig1)

A line graph depicting change in HbA1c percentage over 24 weeks of treatment. It compares three groups: Repaglinide + Pioglitazone combination, Repaglinide alone, and Pioglitazone alone. The x-axis represents treatment weeks (0 to 24), and the y-axis shows percent change in HbA1c from 0 to -2%. The combination group shows the greatest decrease in HbA1c over time.*

FDA Label Image

Chemical Structure (Repaglinide Str)

Chemical structure of repaglinide showing its molecular configuration with labeled atoms and bonds.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.